[1]王竸婧 姚建晗 黄新苗 郭志福 曹江.伊伐布雷定用于心房颤动心室率控制的研究进展[J].心血管病学进展,2024,(12):1066.[doi:10.16806/j.cnki.issn.1004-3934.2024.003]
 WANG Jingjing,YAO Jianhan,HUANG Xinmiao,et al.Ivabradine for Heart Rate Control in Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2024,(12):1066.[doi:10.16806/j.cnki.issn.1004-3934.2024.003]
点击复制

伊伐布雷定用于心房颤动心室率控制的研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年12期
页码:
1066
栏目:
综述
出版日期:
2024-12-25

文章信息/Info

Title:
Ivabradine for Heart Rate Control in Atrial Fibrillation
作者:
王竸婧 姚建晗 黄新苗 郭志福 曹江
(海军军医大学第一附属医院心内科,上海 200433)
Author(s):
WANG JingjingYAO JianhanHUANG XinmiaoGUO ZhifuCAO Jiang
Department of Cardiovasology,First Affiliated Hospital,Naval Medical University,Shanghai 200433,China)
关键词:
心房颤动Funny电流伊伐布雷定室率控制房室结
Keywords:
Atrial fibrillationFunny currentIvabradineHeart rate controlAtrioventricular node
DOI:
10.16806/j.cnki.issn.1004-3934.2024.003
摘要:
控制心室率是心房颤动(AF)治疗的重要方面。目前可用于AF心率控制的药物受到副作用和疗效的限制。伊伐布雷定通过抑制窦房结Funny电流(If),降低窦性。有研究表明,房室结中也存在If通道,阻断房室结If会减慢房室传导,可降低AF的心室率。近期伊伐布雷定用于控制AF心室率治疗引起较多关注。就伊伐布雷定在AF心率控制方面的基础和临床研究做一综述。
Abstract:
Control of ventricular rate is recommended for patients with atrial fibrillation (AF). Currently available agents for rate control in AF are limited by adverse effects and their ability to attain target heart rate. By inhibiting funny current(If)of the sinoatrial nodeivabradine reduces sinus heart rate. However,it has been shown that If channels can also be found in atrioventricular node and blocking atrioventricular nodal If slows AV conduction,resulting in lower ventricular rates during AF. Ivabradine has drawn recent interest as a rate control agent for AF. In this review,we focus on the basic and clinical evidence for ventricular rate control of ivabradine in AF.

参考文献/References:

[1] Writing Committee Members;Joglar JAChung MK,et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2024,83(1):109-279.
[2] Olshansky B,Rosenfeld LE,Warner AL,et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study:approaches to control rate in atrial fibrillation[J]. J Am Coll Cardiol,2004,43(7):1201-1208.
[3] Freeman JV,Reynolds K,Fang M,et al. Digoxin and risk of death in adults with atrial fibrillation:the ATRIA-CVRN study[J]. Circ Arrhythm Electrophysiol,2015,8(1):49-58.
[4] Koruth JS,Lala A,Pinney S,et al. The clinical use of ivabradine[J]. J Am Coll Cardiol,2017,70(14):1777-1784.
[5] 中国医师协会心力衰竭专业委员会国家心血管病专家委员会心力衰竭专业委员会中华心力衰竭和心肌病杂志编辑委员. 伊伐布雷定临床应用中国专家共识J] . 中华心力衰竭和心肌病杂志,2020,4(2)84-91.
[6] Fontenla A,Tamargo J,Salgado R,et al. Ivabradine for controlling heart rate in permanent atrial fibrillation:a translational clinical trial[J]. Heart Rhythm,2023,20(6):822-830.
[7] Turley SL,Francis KE,Lowe DK,et al. Emerging role of ivabradine for rate control in atrial fibrillation[J]. Ther Adv Cardiovasc Dis,2016,10(6):348-352.
[8] Chan YH,Hai JJ,Wong CK,et al. Ventricular rate control with ivabradine in patients with permanent atrial fibrillation[J]. J Interv Card Electrophysiol,2022,65(3):597-599.
[9] Rivolta I,Binda A,Masi A,et al. Cardiac and neuronal HCN channelopathies[J]. Pflugers Arch,2020,472(7):931-951.
[10] Boyett MR,Yanni J,Tellez J,et al. Regulation of sinus node pacemaking and atrioventricular node conduction by HCN channels in health and disease[J]. Prog Biophys Mol Biol,2021,166:61-85.
[11] DiFrancesco D. The role of the funny current in pacemaker activity[J]. Circ Res,2010,106(3):434-446.
[12] Baruscotti M,Bucchi A,Viscomi C,et al. Deep bradycardia and heart block caused by inducible cardiac-specific knockout of the pacemaker channel gene HCN4[J]. Proc Natl Acad Sci U S A,2011,108(4):1705-1710.
[13] Zhou J,Ding WG,Makiyama T,et al. A novel HCN4 mutation,G1097W,is associated with atrioventricular block[J]. Circ J,2014,78(4):938-942.
[14] Chiamvimonvat V,Newman D,Tang A,et al. A double-blind placebo-controlled evaluation of the human electrophysiologic effects of zatebradine,a sinus node inhibitor[J]. J Cardiovasc Pharmacol,1998,32(4):516-520.
[15] Amstetter D,Badt F,Rubi L,et al. The bradycardic agent ivabradine decreases conduction velocity in the AV node and in the ventricles in-vivo[J]. Eur J Pharmacol,2021,893:173818.
[16] Marciszek M,Paterek A,Oknińska M,et al. Effect of ivabradine on cardiac arrhythmias:antiarrhythmic or proarrhythmic?[J].Heart Rhythm,2021,18(7):1230-1238.
[17] Novella Romanelli M,Sartiani L,Masi A,et al. HCN channels modulators:the need for selectivity[J]. Curr Top Med Chem,2016,16(16):1764-1791.
[18] Mesirca P,Alig J,Torrente AG,et al. Cardiac arrhythmia induced by genetic silencing of ’funny’ (f) channels is rescued by GIRK4 inactivation[J]. Nat Commun,2014,5:4664.
[19] Verrier RL,Sobrado MF,Pagotto VP,et al. Inhibition of I(f) in the atrioventricular node as a mechanism for dronedarone’s reduction in ventricular rate during atrial fibrillation[J]. Heart Rhythm,2013,10(11):1692-1697.
[20] Verrier RL,Silva AF,Bonatti R,et al. Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation[J]. J Cardiovasc Electrophysiol,2015,26(3):329-335.
[21] Saeed Y,Temple IP,Borbas Z,et al. Structural and functional remodeling of the atrioventricular node with aging in rats:the role of hyperpolarization-activated cyclic nucleotide-gated and ryanodine 2 channels[J]. Heart Rhythm,2018,15(5):752-760.
[22] Kosiuk J,Oebel S,John S,et al. Ivabradine for rate control in atrial fibrillation[J]. Int J Cardiol,2015,179:27-28.
[23] Caminiti G,Fossati C,Rosano G,et al. Addition of ivabradine to betablockers in patients with atrial fibrillation:effects on heart rate and exercise tolerance[J]. Int J Cardiol,2016,202:73-74.
[24] Wongcharoen W,Ruttanaphol A,Gunaparn S,et al. Ivabradine reduced ventricular rate in patients with non-paroxysmal atrial fibrillation[J]. Int J Cardiol,2016,224:252-255.
[25] Katheria A,Kapoor A,Sahu A,et al. A pilot study evaluating the role of ivabradine for rate control in patients with rheumatic atrial fibrillation[J]. Indian Heart J,2023,75(5):376-382.
[26] Agakishiev D,Arriola-Montenegro J,Tandon R,et al. Heart rate lowering for coronary CTA with ivabradine in atrial fibrillation[J]. J Cardiovasc Comput Tomogr,2024,18(1):109-110.
[27] Vora A,Kapoor A,Nair M,et al. Clinical presentation,management,and outcomes in the Indian Heart Rhythm Society-Atrial Fibrillation (IHRS-AF) registry[J]. Indian Heart J,2017,69(1):43-47.
[28] Hardison E,Cox ZL,Heckman K,et al. A case report of ivabradine used for heart rate control of atrial fibrillation in acute decompensated heart failure[J]. Eur Heart J Case Rep,2022,6(2):ytac077.
[29] Fontenla A,Villagraz L,de Juan J,et al. Ivabradine as an alternative to AV node ablation in a patient with permanent atrial fibrillation[J]. Rev Esp Cardiol (Engl Ed),2017,70(11):1019-1020.
[30] Pichler P,Pichler-Cetin E,Vertesich M,et al. Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography[J]. Am J Cardiol,2012,109(2):169-173.
[31] Lu Y,Li K,Liu XS,et al. Ivabradine and atrial fibrillation:a double-edged sword[J]. Int J Cardiol,2016,223:182-185.
[32] Suenari K,Cheng CC,Chen YC,et al. Effects of ivabradine on the pulmonary vein electrical activity and modulation of pacemaker currents and calcium homeostasis[J]. J Cardiovasc Electrophysiol,2012,23(2):200-206.
[33] Abdel-Salam Z,Nammas W. Atrial fibrillation after coronary artery bypass surgery:can ivabradine reduce its occurrence?[J]. J Cardiovasc Electrophysiol,2016,27(6):670-676.
[34] Tanbo?a ?H,Top?u S,Aksakal E,et al. The risk of atrial fibrillation with ivabradine treatment:a meta-analysis with trial sequential analysis of more than 40 000 patients[J]. Clin Cardiol,2016,39(10):615-620.
[35] Liu J,Noble PJ,Xiao G,et al. Role of pacemaking current in cardiac nodes:insights from a comparative study of sinoatrial node and atrioventricular node[J]. Prog Biophys Mol Biol,2008,96(1-3):294-304.

备注/Memo

备注/Memo:
收稿日期:2024-06-13 基金项目:上海市申康医院发展中心《促进市级医院临床技能与临床创新能力三年行动计划》项目(SHDC2020CR1040B-4)
更新日期/Last Update: 2025-01-08